<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04176523</url>
  </required_header>
  <id_info>
    <org_study_id>17180</org_study_id>
    <nct_id>NCT04176523</nct_id>
  </id_info>
  <brief_title>Understanding the Long-Term Management of Organic Acidemia Patients With CARBAGLU®: A Mixed Methods Approach</brief_title>
  <acronym>PROTECT</acronym>
  <official_title>Understanding the Long-Term Management of Organic Acidemia Patients With CARBAGLU®: A Mixed Methods Approach</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Recordati Rare Diseases</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Recordati Rare Diseases</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective mixed-design study focused on the long-term management of propionic
      aciduria (PA) and methylmalonic aciduria (MMA) with N-carbamylglutamate (NCG) maintenance
      therapy. Treatment characteristics, clinical outcomes, and healthcare utilization data of
      patients diagnosed PA or MMA treated &gt;6 months therapy with NCG are collected at baseline, 12
      months, and 18 months. Qualitative interviews with adult patients and caregivers are
      conducted &gt;6 months after study enrollment to gain a better understanding of the disease
      burden and the treatment burden of patients and their families.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design: This is a prospective, longitudinal, observational study of patients diagnosed
      with organic acidemia that has been on treatment with carglumic acid for a minimum of six
      months for the long-term management of their disease. This prospective observational study
      population will include up to 40 diagnosed MMA or PA patients with current carglumic acid
      treatment experience from 6 European countries: Sweden, the United Kingdom (UK), the
      Netherlands, Germany, Norway, Italy, Spain and France. The patients (or caregivers) included
      in this prospective observational study will also be invited to participate in a one-on-one
      phone interview.

      Study Procedures: After Institutional Review Board (IRB)/Independent Ethics Committee (IEC)
      approval is obtained for the protocol and all supporting protocol documents, clinicians
      caring for patients with MMA or PA will provide their patients (or caregivers) with the
      opportunity to participate in the study. Patients (or caregivers) will receive an Information
      Letter (PIL) (Appendices A and B) inviting them (or their caregiver) to take part in a
      prospective observational study and in a one-on-one phone interview.

      Patients (or caregivers) who are interested in participating in this observational/interview
      study will review the informed consent form (Appendices C and D) with the clinician and
      his/her research team. If agreeable, patients (or caregivers) will be asked to sign the
      consent form and a countersigned copy will be provided to them for their records. Clinicians
      and their research team at each site will then review patient charts and record demographic
      and medical history information for each patient. Patient information from medical charts
      will be collected at the start of the study (baseline), and 12 months and 18 months after
      baseline. All information derived from medical chart reviews will be recorded through
      web-based Electronic Data Capture system (EDC).

      Patients (or caregivers) who agree to participate in a one-on-one phone interview will
      provide contact information for their clinicians and the respective research team to include
      in the Contact Information Form (CIF) (Appendix E). Researchers will then contact patients
      (or caregivers) directly to schedule a one-hour phone interview. An interview guide
      (Appendices F and G) including open-ended questions and probes will be used to elicit
      concepts and orient the discussion during the interview. Patient (or caregiver) interviews
      will focus on describing the symptoms and impacts of MMA or PA, as well as patient treatment
      experiences with carglumic acid, their treatment preferences, and their satisfaction with
      treatment. At the end of the interview, patients (or caregivers) will be asked to complete a
      Demographic and Health Information Form (DHIF; Appendices H and I). Phone interviews will be
      audio-recorded with the patient's (or caregiver) permission, transcribed and translated (as
      needed) in preparation for qualitative analysis.

      Data Analysis: The primary prospective data analysis will involve a comparison of the
      incidence and duration of decompensation episodes pre- and post- initiation of carglumic
      acid. Additional analysis will include healthcare resource utilization around individual
      decompensation events, patient/caregiver burden, and patient/caregiver satisfaction with
      treatment. All prospective data will be undertaken using SAS® software, version 9.4 of the
      SAS® system for Windows (Cary, NC, USA). All qualitative data from the interviews will be
      analyzed using ATLAS.ti, a software package uniquely designed to analyze qualitative data.
      The audio-recorded verbatim transcripts of the interviews will be coded to identify patterns
      in participants' responses concerning patient experiences with the symptoms and impacts of
      MMA or PA, treatment experience with carglumic acid, patient treatment preferences, and
      treatment satisfaction. Findings will be summarized in a final report and may be published or
      presented by the investigator(s) after the review by, and in consultation and agreement with,
      the sponsor. If published or presented, the results will be presented in such a way that
      confidential or proprietary information is not disclosed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 15, 2019</start_date>
  <completion_date type="Anticipated">December 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 15, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Number and Duration of Decompensation Events</measure>
    <time_frame>18 months</time_frame>
    <description>Change in the number of decompensation events before and after treatment with carglumic acid</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency and Duration of Healthcare Resource Utilization</measure>
    <time_frame>18 months</time_frame>
    <description>Estimation of the health care resource utilization associated with a decompensation event with number of inpatient hospitalization vs. outpatient vs. home. Treatment used to control ammonia levels during decompensation episodes. Number of emergency visits. number of visits to specialist or to general practitioner. Number of hospital stays. Number of bed days in hospital.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Caregiver Burden Exposure Frequency and Duration</measure>
    <time_frame>18 months</time_frame>
    <description>description of the patient and caregiver burden associated with MMA and PA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Caregiver Satisfaction Level</measure>
    <time_frame>18 months</time_frame>
    <description>Describe the MMA and PA patient and caregiver satisfaction with MMA or PA treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance Dosage of NCG</measure>
    <time_frame>18 months</time_frame>
    <description>Document the dosages of NCG used in maintenance treatment</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Methylmalonic Acidemia</condition>
  <condition>Propionic Acidemia</condition>
  <arm_group>
    <arm_group_label>Methylmalonic_acidemia</arm_group_label>
    <description>Patients with confirmed diagnosis of methylmalonic acidemia, and treated with carglumic acid, at any dose form, any dosage,</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propionic_Acidemia</arm_group_label>
    <description>Patients with confirmed diagnosis of propionic acidemia, and treated with carglumic acid, at any dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carglumic Acid</intervention_name>
    <description>Maintenance therapy with carglumic acid</description>
    <arm_group_label>Methylmalonic_acidemia</arm_group_label>
    <arm_group_label>Propionic_Acidemia</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with organic acideamia that have been on treatment with CARBAGLU® for a
        minimum of six months for the long-term management of their disease. This prospective
        observational study population will include up to 60 diagnosed MMA or PA patients with
        current carglumic acid treatment experience from 6 European countries: Sweden, the United
        Kingdom (UK), the Netherlands, Germany, Norway, Italy, Spain and France. The patients (or
        caregivers) included in this prospective observational study will also be invited to
        participate in a one-on-one phone interview.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient has confirmed diagnosis of an organic acidemia (e.g., MMA or PA)

          2. Patient initiated treatment with carglumic acid for long-term management of MMA or PA

          3. Patient has been treated with carglumic acid for a minimum of 6 months

          4. Patient (or caregiver) is able to comply with all prospective study procedures

          5. Patient (or caregiver) is able to provide informed consent

        Exclusion Criteria:

          -  None
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>99 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Sufin Yap, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sheffield Children's NHS Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vincenzo Giordano, MD</last_name>
    <phone>33 1 79911282</phone>
    <email>giordano.v@recordati.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hopital Des Enfants, CHU de Bordeaux-GH Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Delphine Lamireau, MD</last_name>
      <phone>05.56.79.56.46</phone>
      <email>delphine.lamireau@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital de la Conception</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karin Mazodier, MD</last_name>
      <phone>04.91.38.23.79</phone>
      <email>Karin.MAZODIER@ap-hm.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Nancy - Hopitaux de Brabois</name>
      <address>
        <city>Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francois Feillet, MD</last_name>
      <phone>03.83.15.47.96</phone>
      <email>f.feillet@chru-nancy.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Torre, MD</last_name>
      <phone>02.32.88.07.66</phone>
      <email>stephanie.torre@chu-rouen.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nouvel Hopital Civil</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Esther Noel, MD</last_name>
      <phone>03.88.11.62.52</phone>
      <email>Esther.NOEL@chru-strasbourg.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital de Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Therese Abi-Warde, MD</last_name>
      <phone>03.88.12.83.28</phone>
      <email>Marie-Therese.ABIWARDE@chru-strasbourg.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Policlinico di Bari</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albina Tummolo, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Meyer</name>
      <address>
        <city>Firenze</city>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Alice Donati, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>San Paola Hospital, ASST Santi Paolo e Carlo</name>
      <address>
        <city>Milan</city>
        <zip>20142</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabrina Paci, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera San Gerardo Monza</name>
      <address>
        <city>Monza</city>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Serena Gasperini, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Federico II</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giancarlo Parenti, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0372</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trine Tangeraas, MD</last_name>
      <phone>0047 23 07 78 20</phone>
      <email>ttangera@ous-hf.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Infantil Universitario Nino Jesus</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elvira Canedo-Villarroya, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Consuelo Pedron-Giner, MD</last_name>
      <phone>0034 915 03 59 33</phone>
      <email>consuelocarmen.pedron@salud.madrid.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Martin-Hernandez, MD</last_name>
      <phone>0034 913 90 88 86</phone>
      <email>emartinhernandez@salud.madrid.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Morais-Lopez, MD</last_name>
      <phone>0034 917 27 73 01</phone>
      <email>ana_morais_lopez@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Arrixaca</name>
      <address>
        <city>Murcia</city>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Gil-Ortega, MD</last_name>
      <phone>0034 609 08 23 44</phone>
      <email>d.gil.ortega@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Son Espases</name>
      <address>
        <city>Palma De Mallorca</city>
        <zip>07010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angeles Ruiz-Gomez, MD</last_name>
      <phone>0034 659 71 96 81</phone>
      <email>ma.ruiz@ssib.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Bueno-Delgado, MD</last_name>
      <phone>0034 616 11 98 97</phone>
      <email>mbuenod@yahoo.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guy's and St. Thomas' Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roshini Vara, MD</last_name>
      <phone>+44 ‭(0)20 7188 9412‬</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital</name>
      <address>
        <city>London</city>
        <zip>WC1N3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Davidson, MD</last_name>
      <phone>44 207 4059200</phone>
      <email>james.davison@gosh.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sheffield Children's Hospital NHS Foundation Trust</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sufin Yap, MD</last_name>
      <email>sufin.yap@nhs.net</email>
    </contact>
    <contact_backup>
      <last_name>Laura Looby</last_name>
      <phone>‭‭‭+44 (0)115 ‭‭‭924 9924</phone>
      <email>laura.looby@nuh.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Sufin Yap, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
    <country>Norway</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>November 20, 2019</study_first_submitted>
  <study_first_submitted_qc>November 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 25, 2019</study_first_posted>
  <last_update_submitted>January 8, 2020</last_update_submitted>
  <last_update_submitted_qc>January 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propionic Acidemia</mesh_term>
    <mesh_term>Acidosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

